Get the Stockscreener App
8.28
0.18%
0.015
After Hours:
8.28
Amneal Pharmaceuticals Inc stock is traded at $8.28, with a volume of 985.61K.
It is up +0.18% in the last 24 hours and down -1.19% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$8.265
Open:
$8.28
24h Volume:
985.61K
Relative Volume:
0.70
Market Cap:
$2.59B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-12.17
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
-4.39%
1M Performance:
-1.19%
6M Performance:
+1.10%
1Y Performance:
+36.63%
1-Day Range:
$8.195
$8.40
1-Week Range:
$8.18
$8.9499
52-Week Range:
$5.18
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
8.28 | 2.59B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
163.11 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.05 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.24 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.08 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.81 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Myasthenia Gravis Treatment Market Size, Growth Analysis 2031 - openPR
Insiders At Amneal Pharmaceuticals Sold US$48m In Stock, Alluding To Potential Weakness - Simply Wall St
Amneal Digs Deeper Into GLP-1 Aspirations Following Metsera’s IPO - Citeline
Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued (NASDAQ:AMRX) - Seeking Alpha
Amneal Pharmaceuticals (AMRX) Stock Soars 45% on Success of New Parkinson’s Treatment - Markets Insider
Amneal Pharmaceuticals’ SWOT analysis: generic drug maker’s stock poised for growth By Investing.com - Investing.com South Africa
Amneal Pharmaceuticals’ SWOT analysis: generic drug maker’s stock poised for growth - Investing.com
Amneal at Barclays Healthcare Conference: Growth and Innovation Insights By Investing.com - Investing.com UK
Amneal to Participate at Upcoming March 2025 Investor Conference - BioSpace
Amneal to Participate at Upcoming Investor Conference - WICZ
Amneal Pharmaceuticals CEO Set for Key Presentation at Barclays Healthcare Conference - StockTitan
Amneal Pharmaceuticals EVP Jason Daly sells $792,159 in stock By Investing.com - Investing.com Australia
Amneal Pharmaceuticals EVP Andrew Boyer sells $1.1 million in stock By Investing.com - Investing.com Australia
Insider Exodus: Amneal Pharmaceuticals Executives and Directors Offload Massive Stock Holdings - TipRanks
Amneal Pharmaceuticals EVP Jason Daly sells $792,159 in stock - Investing.com
Amneal Pharmaceuticals CFO Tasos Konidaris sells $891,000 in stock By Investing.com - Investing.com Canada
Teva denied stay in Amneal patent dispute as it appeals to Supreme Court - MLex
Amneal Pharmaceuticals EVP Andrew Boyer sells $1.1 million in stock - Investing.com
Amneal Pharmaceuticals CFO Tasos Konidaris sells $891,000 in stock - Investing.com
Amneal Pharmaceuticals director Alva Emily Peterson sells $712,000 in stock - Investing.com
Amneal Pharmaceuticals Executives and Director Sell Shares - TradingView
Polycystic Ovarian Syndrome Treatment Market Set for USD 4.3 Billion by 2034 as Demand for Personalized Medicine Rises | Exclusive Report by TMR - GlobeNewswire Inc.
Amneal’s Rytary Follow-On Crexont Could Hit $500m In Sales - Insights
Principal Financial Group Inc. Purchases 8,213 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal Pharmaceuticals director Patel sells $712,000 in stock By Investing.com - Investing.com South Africa
Amneal Pharmaceuticals director Patel sells $712,000 in stock - Investing.com India
Amneal Receives FDA Approval for Lenalidomide - Clinical Oncology News
Amneal Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers - The Globe and Mail
US Denosumab Race Remains Busy As Amneal And mAbxience See Filing Accepted - Citeline
Handelsbanken Fonder AB Acquires Shares of 39,000 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Rhumbline Advisers Purchases 7,875 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal Pharmaceuticals (NASDAQ:AMRX) Given New $11.00 Price Target at Barclays - Defense World
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA - BioSpace
Full Fed. Circ. Won't Take On Teva's Orange Book Appeal - Law360
Amneal projects $3B-$3.1B revenue in 2025 with biosimilars and CREXONT as key drivers - MSN
Amneal, mAbxience's Biologics Licensing Application for Denosumab Biosimilars Accepted for Review by FDA - Marketscreener.com
Amneal seeks FDA nod for bone therapy biosimilars By Investing.com - Investing.com South Africa
Amneal seeks FDA nod for bone therapy biosimilars - Investing.com
Amneal Pharmaceuticals BLA submissions for denosumab biosimilars accepted by FDA - TipRanks
Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA - Marketscreener.com
New York State Common Retirement Fund Boosts Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Analysts Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) PT at $10.60 - Defense World
JP Morgan Upgrades Amneal Pharmaceuticals (AMRX) - MSN
Amneal Pharmaceuticals’ Earnings Call Highlights Robust Growth - MSN
Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Weight Loss Drug Stock to Buy According to Analysts? - Insider Monkey
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):